[Problem]A compound which is useful as an inhibitor on EGFR T790M mutation kinase activity is provided.[Means for Solution]The present inventors have investigated a compound having an inhibitory action on an EGFR T790M mutation kinase, and have found that a pyrazinecarboxamide compound has an inhibitory action on an EGFR T790M mutation kinase, thereby completing the present invention. The pyrazinecarboxamide compound of the present invention has an inhibitory action on an EGFR T790M mutation kinase, and can be used as an agent for preventing and/or treating EGFR T790M mutation positive cancer, in another embodiment, EGFR T790M mutation positive lung cancer, in a still other embodiment, EGFR T790M mutation positive non-small cell lung cancer, in further still another embodiment, EGFR T790M mutation protein positive cancer, in further still another embodiment, EGFR T790M mutation protein positive lung cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant lung cancer, and in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer, or the like.本發明之課題為提供可用於作為EGFR T790M突變激酶活性之抑制劑的化合物。本發明者等人針對具有EGFR T790M突變激酶之抑制作用的化合物進行檢討,確認到吡羧醯胺化合物具有EGFR T790M突變激酶之抑制作用,而完成本發明。本發明之吡羧醯胺化合物具有EGFR T790M突變激酶之抑制作用,可使用作為EGFR T790M突變陽性癌、其他態樣之EGFR T790M突變陽性肺癌、其他態樣之EGFR T790M突變陽性非小細胞肺癌、其他態樣之EGFR T790M突變蛋白質陽性癌、其他態樣之EGFR T790M突變蛋白質陽性肺癌、其他態樣之EGFR酪胺酸激酶抑制劑抗性的癌、其他態樣之EGFR酪胺酸激酶抑制劑抗性的肺癌、其他態樣之EGFR酪胺酸激酶抑制劑抗性的非小細胞肺癌等的預防及/或治療劑。
